{
    "clinical_study": {
        "@rank": "121030", 
        "arm_group": {
            "arm_group_label": "Icotinib+WBRT", 
            "arm_group_type": "Experimental", 
            "description": "Standard whole brain radiotherapy is given with 4000cGY/20 times, plus icotinib, which was administered orally three times per day."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of icotinib in combination\n      with whole brain radiotherapy for NSCLC patients with brain metastases. The primary endpoint\n      is objective response rate of intracranial lesions."
        }, 
        "brief_title": "Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small-cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histological or cytological confirmation of non-small-cell lung cancer (NSCLC).\n\n          -  Diagnosis of non-systematic brain metastases on a Gadolinium-enhanced MRI. More than\n             2 sites of intracranial metastases, or the longest diameter of the intracranial\n             lesion is more than 3cm.\n\n          -  No other metastases except for brain metastases.\n\n        Exclusion Criteria:\n\n          -  Previous usage of EGFR-TKI or antibody to EGFR: gefitinib, erlotinib, herceptin,\n             erbitux.\n\n          -  CSF or MRI findings consistent with metastases of spinal cord, meninges or meningeal."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01926171", 
            "org_study_id": "BD-IV-49"
        }, 
        "intervention": {
            "arm_group_label": "Icotinib+WBRT", 
            "description": "Standard whole brain radiotherapy is given with 4000cGY/20 times, plus icotinib, which was administered orally three times per day.", 
            "intervention_name": "Icotinib+WBRT", 
            "intervention_type": "Drug", 
            "other_name": [
                "Commana", 
                "BPI-2009"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 19, 2013", 
        "location": {
            "contact": {
                "last_name": "Wei Zhu, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Baotou", 
                    "country": "China", 
                    "state": "Inner Mongolia"
                }, 
                "name": "Baotou Central Hospital"
            }, 
            "investigator": {
                "last_name": "Wei Zhu, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single Center, Open Label, Multicenter Study to Determine the Safety and Efficacy of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases", 
        "overall_contact": {
            "last_name": "Wei Zhu, MD", 
            "phone": "86-18686111667"
        }, 
        "overall_official": {
            "affiliation": "Baotou Central Hospital", 
            "last_name": "Wei Zhu, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of participants with an objective response. An objective response (OR) was defined as a patient having a best overall response of either complete response (CR) or partial response (PR) according to RECIST, confirmed at least 28 days following the date of the initial response.", 
            "measure": "Objective response rate of intracranial lesions", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01926171"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of participants with an objective response of extracranial lesions. An objective response (OR) was defined as a patient having a best overall response of either complete response (CR) or partial response (PR) according to RECIST, confirmed at least 28 days following the date of the initial response.", 
                "measure": "Objective response rate of extracranial lesions", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "All cause progress or mortality", 
                "measure": "Progression-free survival of intracranial lesions", 
                "safety_issue": "No", 
                "time_frame": "3-6 months"
            }, 
            {
                "description": "All cause adverse events (AEs) and serious adverse events (SAEs)", 
                "measure": "Safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "6-12 months"
            }
        ], 
        "source": "Betta Pharmaceuticals Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Betta Pharmaceuticals Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}